Bio-Synthesis: Forging New Quality Productive Forces | Strategic Cooperation Between Sinopep and Vazyme

Sinopep (688076.SH) and Vazyme (688105.SH) recently entered into a strategic partnership and established a joint venture (JV) to jointly advance their business development in the field of synthetic biology. This collaboration marks Sinopep' expansion into a synthetic biology technology platform, building upon its existing small molecule, peptide, and oligonucleotide technology platforms. Sinopep places high strategic importance on constructing innovative scientific platforms. By implementing interdisciplinary approaches and a platform-driven strategy, Sinopep aims to achieve industrial upgrade, enhance its technological and manufacturing advantages in pharmaceutical products, and consolidate its leadership position in specialized market segments.

Biosynthesis represents a cutting-edge field in biological research, with biocatalysis by enzymes at its core. Compared to traditional chemical reactions, enzyme-catalyzed processes demonstrate significant advantages, including environmental-friendliness, heightened safety, remarkable specificity, and superior atom economy. Biosynthesis has emerged as a pivotal technology in the global "green synthesis" domain, marking a groundbreaking technological direction.

Synthetic biology builds upon the scientific leap from "understanding life" to "designing life." By integrating enzyme engineering and genetic engineering techniques, it enables the artificial design and synthesis across multiple levels—from gene fragments, DNA molecules and genetic regulatory networks to signal transduction pathways, and cellular systems. This approach ultimately facilitates the industrial-scale production of complex natural products through biological methods.

According to a McKinsey Global Institute report, 60% of industrial products could be manufactured using biotechnology in the future. The bio-intelligent manufacturing revolution driven by synthetic biology is projected to generate $2-4 trillion in annual direct economic value globally between 2030 and 2040.

The 2024 National People's Congress (NPC) Government Work Report positions bio-manufacturing—centered on synthetic biology—as a new engine for economic growth. Synthetic biology is revolutionizing traditional production modes across pharmaceuticals, food, agriculture, and beyond through novel products and processes. It is emerging as the next productivity catalyst following the AI industrial wave, representing the developmental pathway for new quality productive forces.

Figure: Partial estimate of range of annual potential direct economic impact by domain（$ trillion）

（Source: The Bio Revolution: Innovations transforming economies,societies, and our lives）

The establishment of this strategic partnership marks a significant advancement not only for Sinopep (688076.SH) and Vazyme (688105.SH) in business expansion and technological innovation, but also unlocks new development opportunities for the broader pharmaceutical industry. We anticipate that their future explorations in synthetic biology will generate substantial impact not only within biopharmaceuticals, but also extend considerable influence across animal healthcare, agriculture, and other fields. The joint venture will be majority-controlled by Sinopep.

About Sinopep

Sinopep (688076.SH) is a leading, technology driven company specialized in developing and manufacturing Peptides, Oligonucleotides and small molecules intermediates, APls and drug products. With about 15 years of diverse and extensive experience, we have provided high quality products and services to multinational pharmaceutical corporations and biotechnology companies around the world from preclinical to commercial stages. Sinopep currently has three R&D centers supporting manufacturing projects across two manufacturing sites, which met high global quality and EHS standards, and are approved by US FDA and EDOM.

About Vazyme

Vazyme (688105.SH) is a global technology and service provider that dedicated to the design, manufacture, and application of bioactive proteins and continuously expands the application fields of core technologies in life science, in vitro diagnostics, bio-medicine, and others. To meet the varying needs of our customers and partners, we have developed over 600 types of genetically engineered recombinant enzymes and over 2,500 types of high-performance materials and over 2,000 end products. While remaining steadfast to high quality standards, producing all core materials in-house and adhering to GMP quality control standards, we endeavor to maintain a stable and sufficient supply for global customers by establishing subsidiary companies and local warehouses.